Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data presented by Dana-Farber's Ann Partridge, MD.
The common study was a randomized clinical trial aiming to compare guideline concordant care for low risk DCIS to active monitoring or follow up with. Imaging and breast exams, along with the option of endocrine therapy to manage low risk DCIS. The study has shown so far in two-year follow-up that disease outcomes are similar and that active monitoring is not inferior to guideline concordant care for the management of DCIS. The quality of life or PRO outcomes now have shown that similarly, the groups are quite comparable at least in two-year follow-up for issues like anxiety, depression, worries. About breast cancer or DCIS and overall health-related quality of life and breast cancer symptoms. The implications of the PRO analysis from the comet trial suggest that Women who undergo either active monitoring or guideline concordant care have very similar quality of life outcomes, ranging from their overall health related quality of life to pain and breast cancer related symptoms in the at least 2-year follow-up. It's really important that we study this because if active monitoring is something that we are ultimately finding safe in the long term, then we know that when women are making choices to undergo guideline concordant care or active monitoring, that at least for now in the short term, they can anticipate that their average quality of life would be comparable.
